- Home
- BIRD vs ABOS Comparison
BIRD vs ABOS Comparison
Compare BIRD & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- ABOS
- Stock Information
- Founded
- BIRD 2015
- ABOS 1996
- Country
- BIRD United States
- ABOS United States
- Employees
- BIRD N/A
- ABOS N/A
- Industry
- BIRD Apparel
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- ABOS Health Care
- Exchange
- BIRD Nasdaq
- ABOS Nasdaq
- Market Cap
- BIRD 89.7M
- ABOS 82.4M
- IPO Year
- BIRD 2021
- ABOS 2021
- Fundamental
- Price
- BIRD $7.03
- ABOS $1.42
- Analyst Decision
- BIRD Buy
- ABOS Strong Buy
- Analyst Count
- BIRD 2
- ABOS 3
- Target Price
- BIRD $11.00
- ABOS $6.33
- AVG Volume (30 Days)
- BIRD 71.5K
- ABOS 314.6K
- Earning Date
- BIRD 08-07-2025
- ABOS 08-12-2025
- Dividend Yield
- BIRD N/A
- ABOS N/A
- EPS Growth
- BIRD N/A
- ABOS N/A
- EPS
- BIRD N/A
- ABOS N/A
- Revenue
- BIRD $170,646,000.00
- ABOS N/A
- Revenue This Year
- BIRD N/A
- ABOS N/A
- Revenue Next Year
- BIRD $5.16
- ABOS N/A
- P/E Ratio
- BIRD N/A
- ABOS N/A
- Revenue Growth
- BIRD N/A
- ABOS N/A
- 52 Week Low
- BIRD $3.93
- ABOS $0.86
- 52 Week High
- BIRD $18.33
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- BIRD 34.55
- ABOS 53.03
- Support Level
- BIRD $6.55
- ABOS $1.24
- Resistance Level
- BIRD $10.54
- ABOS $1.50
- Average True Range (ATR)
- BIRD 0.78
- ABOS 0.11
- MACD
- BIRD -0.36
- ABOS -0.01
- Stochastic Oscillator
- BIRD 22.28
- ABOS 56.10
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.